Thomas Cahill insider trades
Open-market stock purchases and sales by Thomas Cahill, Director at Prime Medicine, Inc, from SEC Form 4 filings since Oct 24, 2022.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -83%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 5, 2026 | PRME Prime Medicine, Inc | Bought (not open market) | — |
Companies traded
- PRME Prime Medicine, Inc: 1 buy, last Jun 5, 2026